Drugs / Apelin
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02259686 | Nov 2014 → May 2015 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02724566 | May 2016 → Apr 2017 | type 2 diabetes mellitus | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 1 | NCT02033473 | Jan → Oct 2014 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03449251 | Mar 2018 → Sep 2025 | cardiovascular disorder, type 2 diabetes mellitus | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT01457170 | Jan 2012 → Jan 2014 | heart failure, pulmonary arterial hypertension | Golden Jubilee National Hospital | Unknown | No outcome recorded |
| — | NCT01179061 | Aug 2010 → Jul 2012 | heart failure | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00901719 | Apr → May 2010 | heart failure | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00901888 | Apr 2009 → May 2010 | heart disorder, isoproterenol-mediated vasodilatation | University of Edinburgh | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00901888 ↗ |
| Known as | (PYR1)-apelin-13 | “The (PYR1)-apelin-13 is an endogenous peptide discovered relatively recently (1998).” NCT02033473 ↗ |
| Action | Activate | “Apelin receptor agonist” CHEMBL4650373 ↗1“APJ agonism” PMID 23519586 ↗ Mar 2013 |
| Modality | Peptide | “6 hour infusion of apelin peptide into circulation” NCT01179061 ↗ |
| Route | Other | “Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.” NCT00901719 ↗ |
| Target | APLNR | “Apelin receptor agonist” CHEMBL4650373 ↗ |